Gilead Added To Our 2023 Model Portfolio (Technical Analysis) (NASDAQ:GILD)

Maker Of Coronavirus Trial Drug Remdesivir, Gilead Sciences. Inc., Reports Positive Data Coming From Trials

Justin Sullivan

Gilead (NASDAQ:GILD) has our proprietary fundamental and technical Buy Signal, so we have added it to our Model Portfolio. A quick check with Seeking Alpha’s quantitative ratings shows high grades for Profitability, Revisions and Momentum.

Naturally we

Buy signal peaked and is dropping

Gilead: Outperformer In A Bear Market (StockCharts.com)

Be the first to comment

Leave a Reply

Your email address will not be published.


*